Loading...
Search Filters

Date Range

to

Report Types

ALL
RCT
META
ACE Reviews

Condition

See all (6)

Region of the Body

Specialties

See all (14)

Multimedia

Journal

Conference Series

Evidence Series

We found 20 results matching your search query: "Denosumab"

Showing 1 - 20 of 20
Read Ace Report

Denosumab reduces risk of fractures in post-menopausal women

N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Axial Skeleton Spine Spine Lumbar Fracture Amgen AstraZeneca Aventis Eli Lilly GlaxoSmithKline Merck Nordic Bioscience Novartis Procter & Gamble Roche Sanofi Denosumab Placebo Subcutaneous Injection - Hide
Read Ace Report

FREEDOM RCT follow-up: Denosumab does not delay fracture healing in osteoporosis patients

J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Axial Skeleton Spine Spine Lumbar Lower Extremity Hip Fracture Amgen Denosumab Placebo Subcutaneous Injections Supplementation Of Calcium Vitamin - Hide
Read Ace Report

Denosumab increases bone mineral density in male patients with low BMD

J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21

RCT Metabolic Disorders Denosumab Placebo Subcutaneous Injection - Hide
Read Ace Report

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Amgen Denosumab Intravenous Injection Oral Subcutaneous Injections ZOL Zoledronic Acid - Hide
Read Ace Report

Denosumab is superior to alendronate for improving cortical bone porosity post-menopause

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

RCT Metabolic Disorders Postmenopausal Women Axial Skeleton Spine Spine Lumbar Lower Extremity Hip Amgen Merck Alendronate Denosumab Cortical Placebo Subcutaneous Injection - Hide
Read Ace Report

Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies

J Clin Densitom. 2016 Jul-Sep;19(3):346-51

RCT Metabolic Disorders Osteopenia Osteoporosis Postmenopausal Women Fracture Amgen Eli Lilly Denosumab Teriparatide - Hide
Read Ace Report

Denosumab and teriparatide significantly improves BMD in patients with osteoporosis

J Clin Endocrinol Metab. 2014 May;99(5):1694-700

RCT General Orthopaedics Osteoporosis Postmenopausal Women Axial Skeleton Spine Lower Extremity Hip Fracture Amgen Eli Lilly Denosumab Teriparatide - Hide
Read Ace Report

Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Fracture Amgen Risedronate Denosumab Bisphosphonate Ibandronate Oral - Hide
Read Ace Report

WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo

RCT Metabolic Disorders Postmenopausal Women Axial Skeleton Spine Spine Lumbar Lower Extremity Hip Alendronate Denosumab Placebo - Hide
Read Ace Report

Denosumab reduces secondary fragility fracture risk in osteoporotic women

Climacteric. 2015 Jun 1:1-23

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Fracture Amgen GlaxoSmithKline Denosumab Placebo Subcutaneous Injections - Hide
Read Ace Report

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Axial Skeleton Spine Spine Lumbar Lower Extremity Hip Bone Femur Neck Amgen Denosumab Oral ZOL Zoledronic Acid - Hide
Read Ace Report

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Amgen Eli Lilly Denosumab Teriparatide - Hide
Read Ace Report

Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis

Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15

RCT Osteoarthritis Osteoporosis Postmenopausal Women Axial Skeleton Spine Lower Extremity Hip Bone Femur Arthritis Fracture Amgen Eli Lilly Denosumab Teriparatide - Hide
Read Ace Report

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Lower Extremity Hip Bone Femur Joint Vertebral Neck Fracture Amgen UCB Pharma Denosumab Placebo Romosozumab Subcutaneous Injection - Hide
Read Ace Report

Denosumab noninferior to zoledronic acid in the treatment of bone metastasis

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22

RCT Tumour Breast Lesion Metastasis Myeloma Amgen Novartis Infusion Placebo Subcutaneous Injections Of Denosumab Zoledronic Acid - Hide
Read Ace Report

Denosumab increases bone mass but does not reduce fracture risk compared to alendronate

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7

Meta-analysis Metabolic Disorders Osteoporosis Postmenopausal Women Fracture Alendronate Control Denosumab Subcutaneously - Hide
Read Ace Report

Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users

Osteoporos Int. 2016 Jun;27(6):1989-98

Meta-analysis Metabolic Disorders Osteoporosis Fracture Alendronate Risedronate Glucocorticoid Denosumab Teriparatide Zoledronate Raloxifene Calcitonin Calcium Oral Placebo Preventing Replacement Vitamin - Hide
Read Ace Report

Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1

Meta-analysis General Orthopaedics Stroke Lower Extremity Hip Fracture Alendronate Alfacalcidol Control Oral Placebo Preventing Prevention Risendronate - Hide
Read Ace Report

Combined & extended alendronate with teriparatide improves BMD in women with osteoporosis

J Bone Miner Res. 2014 Aug;29(8):1777-85

RCT Metabolic Disorders Osteoporosis Postmenopausal Women Alendronate Teriparatide Raloxifene Calcium Extension Monotherapy - Hide
Read Ace Report

Oral administration of salmon calcitonin for postmenopausal women with low bone mass

Osteoporos Int. 2014 Nov;25(11):2649-56

RCT General Orthopaedics Postmenopausal Women Fracture Tarsa Therapeutics Instructed Oral Placebo Salmon Calcitonin - Hide
Showing 1 - 20 of 20